Surveys and Anatomic Pathology Education Programs

Surveys and Anatomic Pathology Education Programs Performance Improvement Program in Surgical Pathology PIP/PIPW-B 2017 Participant Summary 2017 College of American Pathologists. The College does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The College hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The College prohibits use of the material in the Report and any unauthorized use of the College s name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The College will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the College s name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services.

2017 PIP/PIPW-B PARTICIPANT SUMMARY Program Update This report summarizes the diagnostic responses for set B of the 2017 Performance Improvement Program in Surgical Pathology (PIP & PIPW). A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only. SURGICAL PATHOLOGY COMMITTEE Rochelle A. Simon, MD FCAP, Chair Aaron Auerbach, MD FCAP, Vice Chair Oyedele A. Adeyi, MBBS FCAP Vijayalakshmi Ananthanarayanan, MD FCAP Aleodor Alexandru Andea, MBA, MD FCAP Deborah Ann Belchis, MD FCAP Philip A. Branton, MD FCAP Rajan Dewar, MD, PhD FCAP H. Parry Dilworth, MD FCAP Leslie Dodd, MD FCAP Julie C. Fanburg-Smith, MD FCAP Marisa Rose Nucci, MD FCAP Nilsa C. Ramirez, MD FCAP Kirtee Raparia, MD FCAP Vijaya B. Reddy, MD, MBA FCAP Safia N. Salaria, MD FCAP J. Clint Stanfill, MD Nichole L. Steidler, MD FCAP Justin M. Wells, MD FCAP Danielle E. Westfall, MD FCAP

(1465) Pulmonary adenocarcinoma, predominantly papillary type PIPW Participants Case # 2017-11 1653 Adenocarcinoma in situ, non-mucinous type 53 0.9 1 0.9 1276 Adenocarcinoma, mixed subtype 14 0.2 3 2.9 2738 Adenocarcinoma, NOS 7 0.1 0 0.0 1004 Bronchioalveolar carcinoma 37 0.6 4 3.9 1445 Minimally invasive adenocarcinoma, nonmucinous 12 0.2 0 0.0 type 2064 Pulmonary adenocarcinoma, 198 3.2 16 15.2 predominantly lepidic type 1465 Pulmonary adenocarcinoma, predominantly papillary type 5787 94./8 81 77.1 001 Excellent 3224 56.6 002 1073 18.9 003 Satisfactory 1281 22.5 004 99 1.7 005 Unsatisfactory 15 0.3 (2081) Adult granulosa cell tumor PIPW Participants Case # 2017-12 2081 Adult granulosa cell tumor 6081 99.5 93 93.0 1907 Endometrioid adenocarcinoma 4 0.1 1 1.0 1886 Juvenile granulosa cell tumor 14 0.2 6 6.0 2284 Metastatic carcinoid tumor 2 0.1 0 0.0 2343 Small cell carcinoma, hypercalcemic type 4 0.1 0 0.0 001 Excellent 2962 52.3 002 1161 20.5 003 Satisfactory 1380 24.4 004 144 2.5 005 Unsatisfactory 17 0.3

(1023) Mesoblastic nephroma/congenital mesoblastic nephroma PIPW Participants Case # 2017-13 1499 Clear cell sarcoma, cellular variant 17 0.3 6 6.3 1023 Mesoblastic nephroma/congenital 5948 97.5 75 78.1 mesoblastic nephroma 2079 Metanephric fibroma 96 1.6 11 11.5 1317 Rhabdoid tumor 6 0.1 1 1.0 1369 Wilms tumor, blastema-predominant 32 0.5 3 3.1 001 Excellent 2985 53.3 002 1182 21.2 003 Satisfactory 1305 23.4 004 99 1.8 005 Unsatisfactory 14 0.3 (2401) Cryptococcal pneumonia PIPW Participants Case # 2017-14 1920 Blastomycosis 69 1.1 22 23.1 2240 Coccidiomycosis 71 1.2 14 14.7 2401 Cryptococcal pneumonia 5878 96.2 50 53.0 1615 Histoplasmosis 22 0.4 5 5.1 2131 Pneumocystis pneumonia 65 1.1 4 4.1 001 Excellent 2522 45.2 002 1208 21.7 003 Satisfactory 1556 27.9 004 256 4.6 005 Unsatisfactory 35 0.6

(2389) Leiomyosarcoma PIPW Participants Case # 2017-15 1901 Gastrointestinal stromal tumor 36 0.6 11 12.0 2389 Leiomyosarcoma 6024 98.6 65 70.6 2159 Malignant peripheral nerve sheath tumor 18 0.3 6 6.5 2066 Sarcomatoid carcinoma (spindle 28 0.4 10 10.9 cell/metaplastic urothelial cell carcinoma) 1882 Squamous cell carcinoma with spindle cell component 1 0.1 0 0.0 001 Excellent 2890 51.8 002 1178 21.1 003 Satisfactory 1366 24.5 004 121 2.2 005 Unsatisfactory 24 0.4 (1989) Metastatic prostatic adenocarcinoma PIPW Participants Case # 2017-16 1381 Adenocarcinoma of rete testis/epididymis 59 1.0 10 11.3 1994 Embryonal carcinoma 8 0.1 0 0.0 3011 Metastatic colorectal adenocarcinoma 44 0.7 0 0.0 1989 Metastatic prostatic adenocarcinoma 5958 97.6 70 79.6 2257 Müllerian-type epithelial tumor 12 0.2 5 5.7 2341 Sertoli cell tumor 22 0.4 3 3.4 001 Excellent 2926 52.3 002 1175 21.0 003 Satisfactory 1341 24.0 004 136 2.4 005 Unsatisfactory 12 0.2

(1041) Metastatic pheochromocytoma PIPW Participants Case # 2017-17 1008 Cholangiocarcinoma 4 0.1 0 0.0 2483 Fibrolamellar hepatocellular carcinoma 33 0.5 2 2.3 1850 Metastatic adrenal cortical carcinoma 78 1.3 5 5.8 1674 Metastatic melanoma 8 0.1 2 2.3 1041 Metastatic pheochromocytoma 5979 98.0 77 89.6 001 Excellent 3027 53.7 002 1135 20.2 003 Satisfactory 1335 23.7 004 125 2.2 005 Unsatisfactory 11 0.2 (1819) Mucinous adenocarcinoma PIPW Participants Case # 2017-18 1830 Colitis cystica profunda 1 0.1 0 0.0 1849 Medullary carcinoma 11 0.2 1 1.2 1819 Mucinous adenocarcinoma 6086 99.5 85 98.8 1174 Neuroendocrine neoplasm of the colon 2 0.1 0 0.0 2188 Signet ring cell adenocarcinoma 3 0.1 0 0.0 001 Excellent 3115 55.5 002 1078 19.2 003 Satisfactory 1296 23.1 004 113 2.0 005 Unsatisfactory 13 0.2

(1803) Primary biliary cholangitis PIPW Participants Case # 2017-19 1762 Autoimmune cholangitis 57 0.9 15 17.6 1763 Autoimmune hepatitis 36 0.6 13 15.2 1147 Chronic viral hepatitis C 6 0.1 1 1.2 1803 Primary biliary cholangitis 5819 95.5 46 54.2 1010 Primary sclerosing cholangitis 177 2.9 10 11.8 001 Excellent 2630 47.4 002 1268 22.8 003 Satisfactory 1471 26.5 004 166 3.0 005 Unsatisfactory 17 0.3 (1780) Schwannoma PIPW Participants Case # 2017-20 1646 Leiomyoma 4 0.1 0 0.0 2389 Leiomyosarcoma 7 0.1 1 1.1 2440 Low-grade fibromyxoid sarcoma 77 1.3 10 11.6 2159 Malignant peripheral nerve sheath tumor 13 0.2 5 5.8 2359 Neurofibroma 46 0.8 4 4.7 1780 Schwannoma 5951 97.5 66 76.8 001 Excellent 2839 50.9 002 1186 21.3 003 Satisfactory 1376 24.7 004 153 2.7 005 Unsatisfactory 22 0.4